For anxious pets on the move, Virbac Anxitane offers a calmer ride

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 4:10 PM ET. Details in the imprint.

Summer travel, thunderstorms and fireworks are hitting anxious pets hard again, and one of the quiet winners in veterinary practices is Virbac’s calming supplement Anxitane. The chewable tablets for dogs and cats are built around L-theanine from green tea, aiming to take the edge off stress without the drowsiness or motor impairment that many prescription sedatives can cause. For owners looking for support beyond behavior training alone, the product has become a recurring talking point in clinics and pet forums.

How Virbac positions Anxitane for everyday pet anxiety

Anxitane is marketed by French animal-health specialist Virbac as a palatable, scored chewable available in two sizes - Anxitane S for cats and small dogs and Anxitane M/L for medium and large dogs - to help manage mild to moderate anxiety and fear-related behaviors such as noise phobias, travel stress or tension in multi-pet households. The formulation centers on a defined dose of L-theanine, an amino acid originally extracted from green tea that modulates brain neurotransmitters associated with relaxation, while the chewable format is designed to be given either directly as a treat or with food for better compliance. According to the official Virbac product information, recommended use often spans several weeks, with veterinarians adjusting duration around predictable stressors such as fireworks, veterinary visits or relocation according to Virbac’s product page.

Clinically, L-theanine has attracted attention because it appears to promote alpha-wave activity in the brain and support a calm but alert state, which is precisely the balance many pet owners want when they look for non-sedating solutions. In veterinary practice, Anxitane is typically positioned as part of a multimodal approach that may include desensitization training, environmental adjustments such as safe hiding spots or carrier covers, and, in more severe cases, prescription anxiolytic drugs. Some clinics reference small controlled studies in dogs showing reduced fear behavior and improved score-based assessments of anxiety when L-theanine is used alongside behavior modification, but they also emphasize that individual response varies and that supplements do not replace tailored veterinary diagnosis. For many households, the product’s main appeal lies in being able to start “low-intensity” support early, for example weeks before July 4 fireworks or prior to introducing a rescue animal into a busy home.

Virbac also underscores that Anxitane is not meant to act instantly like an injectable sedative; instead, it is used on a schedule, often twice daily, with some guidance to begin supplementation ahead of predictable stress events. In everyday use, that can mean starting administration days to weeks before known triggers, such as airline travel, kennel stays or seasonal storms, then continuing through the period of increased stress. Because it is sold via veterinary channels and specialist pet retailers rather than as a mass-market grocery item, the brand tends to target owners who already engage regularly with their veterinarian and are open to structured behavior plans, not just stand-alone tablets. This positioning fits Virbac’s broader companion-animal portfolio, where the company combines pharmaceuticals, vaccines and nutraceuticals to anchor long-term preventive care relationships with clinics and pet owners.

Outside Virbac’s own material, pet-health portals and veterinary distributors in North America, Europe and Asia typically list Anxitane with similar indications, emphasizing its role in managing reactions to loud noises, social stress, travel and changes in routine. Retail listings often highlight that the tablets are flavored to be highly palatable for most dogs and cats, aiming to reduce the need for pill pockets or forceful administration. At the same time, labels and practice guidelines stress that owners should watch for gastrointestinal upset or unusual behavior changes and discontinue use if adverse reactions appear, while also making clear that any persistent or severe anxiety warrants direct veterinary evaluation rather than long-term self-management with over-the-counter products. In the context of a global companion-animal pharmaceuticals market expected to grow steadily on the back of rising pet ownership and “humanization” of pets, Virbac’s behavioral health products, including Anxitane, provide the company with exposure to a category that extends beyond core vaccines and antiparasitics as described in a recent industry report.

Within Virbac’s portfolio, Anxitane complements other preventive and supportive-care brands aimed at keeping dogs and cats healthier and easier to manage in everyday life, thereby reinforcing the company’s role as a one-stop supplier for many veterinary practices. Behaviour-focused products can help clinics broaden their service offering from purely “sick care” to more holistic wellness programs, which, in turn, tend to stabilize revenue and deepen client loyalty. For Virbac, which generates the majority of its sales in companion animals and has been investing in geographic expansion across North America, Latin America and Asia, maintaining a recognized presence in behavioral supplements like Anxitane strengthens its brand equity in a niche where competition from generics and private-label products is gradually increasing. Shares of Virbac (FR0000031577) last traded on Euronext Paris at EUR 486.50 on 06/13/2026, underscoring investors’ continued focus on the broader pet-health growth story rather than any single product line based on current Euronext data.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.